Lung cancer is the most common cancer and the leading cause of cancer-related death worldwide. However, mechanisms of its progression remained unclear and new treatments against this disease are rapidly emerging. As a novel preclinical model, patient-derived organoid (PDO) can also be established from the patient’s tumor tissue and cultured in the laboratory, which preserves the key biological characteristics of the original tumor. Compared to the patient-derived xenograft (PDX) model of lung cancer, the culture success rate is improved, and the time and cost of model establishment are largely reduced. PDO is also expected to provide a more individual model to predict the efficacy of anti-cancer treatment in vitro. This paper summarizes the current application of PDO in the translational research of lung cancer.

肺癌是最常见的癌症，也是全世界癌症相关死亡的主要原因。然而，其进展机制仍不清楚，针对这种疾病的新疗法正在迅速出现。作为一种新型的临床前模型，患者来源的类器官（PDO）也可以从患者的肿瘤组织中建立并在实验室中培养，它保留了原始肿瘤的关键生物学特征。与肺癌患者来源的异种移植（PDX）模型相比，培养成功率提高，模型建立的时间和成本大大降低。PDO也有望提供一个更加个体化的模型来预测体外抗癌治疗的疗效。本文综述了目前PDO在肺癌转化研究中的应用。